Journal
CANCER CELL
Volume 22, Issue 1, Pages 51-65Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.05.019
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC) of Australia
- NHMRC
- GSK
- Leukaemia Foundation
- Cancer Council of Victoria Sir Edward Weary Dunlop Clinical Research Fellowship
Ask authors/readers for more resources
Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant phenotype remains unclear. We show that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of nucleolar disruption and activation of p53-dependent apoptotic signaling. Human leukemia and lymphoma cell lines also show high sensitivity to inhibition of rDNA transcription that is dependent on p53 mutational status. These results identify selective inhibition of rDNA transcription as a therapeutic strategy for the cancer specific activation of p53 and treatment of hematologic malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available